A Phase 1/2 test is ongoing. As for Bristol Myers Squibb, the Mirati acquisition that brought Krazati included another drug candidate in early clinical development for KRAS G12D-mutated solid tumors.

Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal closing expected in 2025. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential.

For instance, its acquisition of Celgene strengthened its ... recent acquisitions of oncology firms RayzeBio and Mirati and neurology firm Karuna have further bolstered its overall pipeline.

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

Seigerman added that Mirati has expressed interest to commercialise on its own, but "we think an acquisition by a larger biopharma name with experience in commercialising oncology assets could be ...

For instance, its acquisition of Celgene strengthened its ... recent acquisitions of oncology firms RayzeBio and Mirati and neurology firm Karuna have further bolstered its overall pipeline.

“However, the upfront acquisition price is a 57% discount to ... and Baxalta before serving as CEO of Ipsen, FerGene—and Mirati, where he oversaw the U.S. launch of KRAS inhibitor Krazati ...

The companies said that David Meek, the former CEO at Mirati and Ipsen and currently ... “After an extensive review process, this acquisition represents the best path forward.” ...

David Meek, former CEO of Mirati Therapeutics and Ipsen ... After an extensive review process, this acquisition represents the best path forward – maximizing value for stockholders and bringing ...

Mirati, meanwhile, said that Krazati brought in just $36 million in the first nine months of 2023, ahead of BMS’ acquisition, and BMS recorded $21 million in sales in the first quarter of 2024.